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(approximately 106 bacteria per cm2). Bacterial challenge resulted in
a weak but signi®cant (p < 0.05) upregulation of hBD-2 mRNA
expression (2.0 6 0.4 after 24 h; 3.0 6 0.7 after 48 h; data represent
fold change versus untreated HSE 6 SEM) as revealed by standard
Real Time RT-PCR analysis. The observation that nonvirulent
bacteria are much weaker inducers of hBD-2 than virulent bacteria,
such as mucoid Pseudomonas aeruginosa (Harder et al, 2000), may
provide a rationale for the fact that only a weak induction of hBD-2
was achieved, although a rather high cell number of E. coli K12
bacteria was applied topically.
To investigate if hBD-2 expression in the epidermis has
functional relevance, we have soaked Apligraf with E. coli growth
medium and subsequently exposed its surface to E. coli followed by
a 24 h incubation at 37°C. Bacterial colonies did not grow on the
epidermal surface of the intact HSE, although colonies clearly
formed on the dermal surface exposed to bacteria following
mechanical separation of the epidermal layer.
In conclusion, the ®ndings of this study suggest that wound
healing involves induction of an intrinsic antibiotic mechanism,
which is also functional in epidermis of tissue-engineered skin.
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Coincident PTCH and BRCA1 Germline Mutations in a
Patient with Nevoid Basal Cell Carcinoma Syndrome and
Familial Breast Cancer
To the Editor
Nevoid basal cell carcinoma syndrome (NBCCS, OMIM no.
109400) is an autosomal dominant disease that is associated with
various developmental anomalies and different types of neoplasms
(Gorlin, 1987). Major manifestations are multiple basal cell
carcinomas (BCC), odontogenic keratocysts, palmar and plantar
dyskeratotic pits, and intracranial calci®cation (Evans et al, 1993;
Shanley et al, 1994). In addition, rib and vertebral malformations,
epidermal cysts, macrocephaly, facial anomalies, ovarian ®bromas,
and cerebellar medulloblastoma are associated with this syndrome.
NBCCS results from germline mutations in the human homolog of
the Drosophila segment polarity gene patched (PTCH) (Hahn et al,
1996; Johnson et al, 1996). PTCH maps to 9q22.3 and codes for a
transmembrane protein (Ptch) that functions as receptor for the
hedgehog family of signaling molecules (Wicking et al, 1999). So
far, more than 60 different PTCH germline mutations have been
found in NBCCS patients. There appears to be no genotype-
phenotype correlation (Wicking et al, 1997).
Here, we report on a 78-y-old woman who has undergone
multiple operations for BCC of the face and trunk since 1979. In
total, more than 300 BCC have been resected. She has also been
repeatedly operated on jaw keratocysts. At the age of 74 y, she
developed a carcinoma of the left breast that was treated by
mastectomy and lymphadenectomy. Histology showed multifocal
manifestation of invasive ductal carcinoma without regional lymph
node metastases or distant metastases [pT2m, pN0 (0/17), pM0,
G2]. Estrogen and progesteron receptors were negative. At present,
the patient is without recurrent breast carcinoma but still suffers
from multiple BCC of the face, neck, and trunk. Her family history
is remarkable as it does not only show NBCCS in both of her
daughters but also reveals a marked clustering of breast carcinomas
and other malignancies (Fig 1).
Breast carcinomas are not typically associated with NBCCS
(Evans et al, 1993; Shanley et al, 1994). We therefore decided to
investigate our patient for PTCH mutation as well as for mutation
of the hereditary breast and ovarian cancer gene BRCA1 (Miki et al,
1994). The patient gave her informed consent to both analyses. All
22 coding exons of PTCH were examined by single strand
con®rmation polymorphism analysis followed by direct sequencing.
A heterozygous transition mutation (c. 3394T>C, nucleotide
numbering according to GenBank accession no. U59464) was
found in the patient's constitutional DNA (Fig 2a). This mutation
translates into an exchange of serine to proline at codon 1132
(S1132P). The identical mutation was detected in one of the
patient's BCC (Fig 2a). We additionally investigated this BCC for
loss of heterozygosity (LOH) at three microsatellite markers from
9q22.3 (D9S287, D9S197, D9S280). LOH analysis was carried out
on DNA puri®ed from microdissected tumor areas. While D9S197
and D9S280 were constitutively homozygous, D9S287 demon-
strated LOH in the BCC (Fig 2b).
Mutational analysis of the entire BRCA1 coding region was
performed by denaturing high pressure liquid chromotography and
DNA sequencing (Arnold et al, 1999). The patient carried a
heterozygous germline mutation within exon 11, i.e., an insertion
of 31 bp at nucleotide 848 (c. 848ins817±847, nucleotide
numbering according to GenBank accession no. U14680) (Fig 2c).
This mutation results in a frameshift and introduces a premature
stop codon at position 247. The same mutation was found in the
patient's daughter (data not shown).
Manuscript received September 28, 2000; accepted for publication
November 9, 2000.
Reprint requests to: Dr. Julia Reifenberger, Department of Dermatol-
ogy, Heinrich-Heine University, Morenstrasse 5, D-40225 DuÈsseldorf,
Germany. Email: reifenbj@rz.uni-duesseldorf.de
472 LETTERS TO THE EDITOR THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Screening of the mutation databases for PTCH (http://www.
cybergene.se/PTCH and http://www.uwcm.ac.uk/uwcm/mg/
search/119447.html) and BRCA1 (http://www.uwcm.ac.uk/
uwcm/mg/search/126611.html and http://www.nhgri.nih.gov./
Intramural_research/Lab_transfer/Bic/) revealed that both muta-
tions detected in our patient have not been reported before. The
PTCH mutation exchanges the hydrophilic amino acid serine by
the imino acid proline within the 11th transmembrane domain. As
the cyclic structure of proline markedly in¯uences protein
con®rmation, this substitution likely changes protein architecture
and thereby causes functional impairment. This assumption is
supported by the ®nding of another missense mutation at codon
1132 (c. 3395C>A: S1132Y) in an unrelated NBCCS patient
(Chidambaram et al, 1996). The BRCA1 mutation results in a
truncated protein that lacks major functional domains, including
those that are involved in double strand break repair.
Only a few individuals with germline mutations in two distinct
tumor suppressor genes have been reported. Among Ashkenazi
Jewish patients with hereditary breast and ovarian cancer, single
individuals were found with germline mutations in BRCA1 and
BRCA2 (Ramus et al, 1997; Moslehi et al, 2000). In addition, a
breast cancer family with germline mutations in BRCA1 and
HMLH1 has been reported (Borg et al, 2000). We have identi®ed
the ®rst patient with coincident PTCH and BRCA1 germline
mutations. Both mutations were penetrant in our patient and one
of her daughters, while several other relatives either suffered from
NBCCS or malignant tumors including breast cancer. Our patient
suggests that double heterozygosity for BRCA1 and PTCH
germline mutations does not markedly accelerate, aggravate, or
change the manifestations of the respective syndromes. Our
molecular genetic results indicate that occasional hereditary cancer
patients need to be analysed for mutations in more than one gene,
in particular those patients whose symptoms and/or family history
do not match a single syndrome.
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Figure 1.The patient's pedigree. Several family
members are affected by NBCCS and/or breast
carcinoma, endometrial carcinoma, and acute
lymphoblastic leukemia. The index patient
reported here is indicated by an arrow.
Figure 2. Results of DNA sequencing and microsatellite analyses.
(A) DNA sequencing of PTCH exon 20 identi®ed a heterozygous T>C
transition at nucleotide 3394 (arrows) in the patient's blood (leukocyte)
DNA (left). The same mutation is present in one of the patient's BCC
(middle) but not in an unrelated healthy person (wild-type, right). In the
patient's BCC, the normal band appears weaker than the mutant band,
suggesting loss of the wild-type allele in the tumor cells. Histologic
inspection of the tissue specimen used for DNA extraction revealed a
tumor cell content of about 70%. Thus, the residual normal sequence is
likely due to contaminating non-neoplastic cells. (B) Microsatellite analysis
of the patient's BCC using DNA extracted from microdissected tumor
tissue. Note LOH at D9S287 (arrow). (C) DNA sequencing of BRCA1
exon 11 identi®ed a heterozygous BRCA1 germline mutation (c.
848ins817±847) in our patient (upper sequence). The wild-type sequence
from a healthy person is shown for reference (lower sequence).
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Is Screening of the Candidate Gene Necessary in Unrelated
Partners of Members of Families with Herlitz Junctional
Epidermolysis Bullosa?
To the Editor:
Epidermolysis bullosa (EB) refers to a heterogeneous group of
mechanobullous disorders, in which minor trauma leads to blister
formation on skin and mucous membranes. Three major groups of
EB have been de®ned based on the level of tissue separation in the
skin: (a) intraepidermal cleavage in EB simplex, (b) cleavage within
the lamina lucida in junctional forms of EB, and (c) separation
below the lamina densa in dystrophic EB (for review see Fine et al,
1999). In a total of 10 different genes mutations have been found
(Pulkkinen and Uitto, 1999). In Herlitz junctional EB (H-JEB)
mutations in the genes LAMA3, LAMB3, and LAMC2 encoding
for laminin 5 subunit polypeptides have been identi®ed (Pulkkinen
& Uitto, 1999). This variant of EB has an incidence of 1:2,500,000
(Fine et al, 1999), suggesting that reoccurence of H-JEB in families
with partners originating from outside of the nuclear family is rare.
Therefore, scanning of the affected gene of the partner for the same
or other mutations is usually not performed in this setting.
We have recently observed a family with a child with H-JEB and
two unaffected siblings. The parents, who originated from the same
geographical area, were heterozygous carriers of the mutation
Q864X in the LAMC2 gene. The affected child was homozygous
for this nonsense mutation and died at the age of 6 mo (Fig 1).
When the sister of the mother became pregnant with a partner
being from a geographically completely different area we calculated
the risk of reoccurence of H-JEB to be 0.0016%, virtually
excluding another affected child. The ®rst newborn from this
union, however, also had junctional EB. Mutation analysis revealed
that the child was compound heterozygous for the maternal
Q864X mutation and a paternal 4 bp deletion at the intron/exon
border of exon 3 (termed 521 + 3del4) in the LAMC2 gene (Fig 2).
The child had some residual laminin 5 as judged by immuno-
Figure 1. Identi®cation of nonsense muta-
tions within exon 17 of LAMC2 in both
families. (A) Pedigree of families 1 and 2. The
proband of family 1 (C1) died at the age of 6 mo,
the patient of family 2 (C2) died at 10 mo. (B)
Heteroduplex bands were observed with polymer-
ase chain reaction (PCR) products spanning exon
17 and ¯anking intronic sequences in all DNA
samples examined, except in child 1 and father 2.
Lane F1, father 1; lane C1, child 1; lane M1,
mother 1; lane F2, father 2; lane C2, child 2; lane
M2, mother 2. (C) Automated direct sequencing
of the PCR products encompassing exon 17
showed in child 1 a homozygous C-to-T transi-
tion at the nucleotide position 2707 resulting in a
change of Gln to a stop codon (Q864X). (D) The
mutation resulted in loss of a restriction site for
Bcl I endonuclease. A 249 bp product represent-
ing the heterozygous allele was observed in all
samples except in the sample of father 2 showing
a faint band resulting from incomplete digestion.
Child 1 shows complete loss of the restriction site
demonstrating homozygosity for the mutation.
Lane MW, molecular weight markers; lane F1,
C1, M1, F2, C2, M2 as shown above; lane N,
undigested control.
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